Clinical Trial Update: Predicting Recurrence in HR+/HER2- Early Breast Cancer

View source ↗

Summary

This clinical trial update from Shengjing Hospital describes a study aiming to predict recurrence in early-stage HR+/HER2- breast cancer, with the study not yet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer

Snippet

Sponsor: Shengjing Hospital | Conditions: Breast Cancer, HR+/HER2- Early-Stage | Status: NOT_YET_RECRUITING